Pediatric irritable bowel syndrome with constipation (IBS-C) can significantly affect quality of life and presents unique treatment and counseling challenges for patients and families. This course reviews evolving management strategies for pediatric IBS-C, including newly approved treatment options and practical considerations for therapy selection. You will be better prepared to evaluate treatment approaches and counsel families on the safe and appropriate use of therapy for pediatric IBS-C.

HOST
Rachel Maynard, PharmD
GameChangers Podcast Host and Lead, Clinical & Partnership Education, CEimpact

GUEST
Christopher Hartley, PharmD, BCPPS
Pediatric Clinical Pharmacy Specialist,
The Johns Hopkins Hospital

GET CE FOR LISTENING!
Stay Compliant. Grow Clinically. Practice with Confidence.

Pharmacist CE Subscription: All your CE in one convenient subscription.All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there’s even more!

The Pharmacist CE Subscription includes:
- Compliance and licensure CE
- GameChangers Clinical Updates
- Practical continuing education across patient care topics

*The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training.

Purchase Now!

PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription.

CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:

• If you are already enrolled in this course, click here to redeem your credit.
• To purchase thePharmacist CE Subscription and claim your CPE credit,click hereor to purchase this course individually, click here.

CPE INFORMATION
Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:
1. Describe current treatment considerations for pediatric IBS-C, including recently approved pharmacologic options.
2. Compare factors that influence treatment selection and family counseling for pediatric IBS-C.

Rachel Maynard and Christopher Hartley have no relevant financial relationships to disclose.

0.075 CEU/0.75 Hr
UAN: 0107-0000-26-300-H01-P
Initial release date: 8/3/2026
Expiration date: 8/3/2029
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram